Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single...
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
About this item
Full title
Author / Creator
Tombal, Bertrand, Prof , Borre, Michael, Prof , Rathenborg, Per, MD , Werbrouck, Patrick, MD , Van Poppel, Hendrik, Prof , Heidenreich, Axel, Prof , Iversen, Peter, Prof , Braeckman, Johan, Prof , Heracek, Jiri, MD , Baskin-Bey, Edwina, MD , Ouatas, Taoufik, PhD , Perabo, Frank, MD , Phung, De, BSc , Hirmand, Mohammad, MD and Smith, Matthew R, Prof
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background The androgen receptor inhibitor enzalutamide is approved for the treatment of metastatic castration-resistant prostate cancer that has progressed on docetaxel. Our aim was to assess the activity and safety of enzalutamide monotherapy in men with hormone-naive prostate cancer. Methods This trial is an ongoing open-label, single-ar...
Alternative Titles
Full title
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
Authors, Artists and Contributors
Author / Creator
Borre, Michael, Prof
Rathenborg, Per, MD
Werbrouck, Patrick, MD
Van Poppel, Hendrik, Prof
Heidenreich, Axel, Prof
Iversen, Peter, Prof
Braeckman, Johan, Prof
Heracek, Jiri, MD
Baskin-Bey, Edwina, MD
Ouatas, Taoufik, PhD
Perabo, Frank, MD
Phung, De, BSc
Hirmand, Mohammad, MD
Smith, Matthew R, Prof
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1751212845
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751212845
Other Identifiers
ISSN
1470-2045,1474-5488
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(14)70129-9
